Entera Bio Ltd
enterabio.comWhat Do They Do?
Develops oral peptide tablet therapies for patients with osteoporosis, hypoparathyroidism, and obesity and metabolic disorders.
10-K for FY2025, filed Mar 27, 2026Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies.…View ↗
Our most advanced product candidate, EB613 (oral teriparatide, or oral PTH[1-34]), is being developed as the first oral, osteoanabolic…View ↗
Our product candidate, EB612, is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for patients with…View ↗
OXM is a naturally occurring GLP-1/Glucagon dual agonist peptide hormone found in the small intestine that acts to suppress appetite…View ↗
How Do They Make Money?
The company earns revenue for research services under an agreement, with revenue spread over the agreement’s duration.
10-K for FY2025, filed Mar 27, 2026Revenues attributed to the research services agreement are recognized over the duration of the research services agreement.View ↗
$42K
-
10-K for FY2025, filed Mar 27, 2026
$42K ↗
Do Revenues Turn Into Profits?
No. It lost $11.4M in FY2025.
10-K for FY2025, filed Mar 27, 2026
−$11.5MView ↗
10-K for FY2025, filed Mar 27, 2026
−$11.4MView ↗
10-K for FY2025, filed Mar 27, 2026
−$7.5MView ↗
How Are They Changing?
Shrinking. Revenue fell 93% in 4 years, from $571K in FY2021 to $42K in FY2025, about 48% a year.
Broadening the pipeline
The older report focused its clinical pipeline on oral parathyroid hormone tablets and described other peptide work as early research. The latest report also details oral peptide programs for metabolic disorders and short bowel syndrome, including work with OPKO.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 27, 2026We currently have two product candidates in the clinical stage of development: EB613 and EB612. Both candidates are first-in-class daily…View ↗
Loading...
